Targeting EGFR mutations using known anti-inflammatory compounds (e.g., curcumin derivatives).
Thu, 24 Apr
|On Going Project
Epidermal Growth Factor Receptor (EGFR) mutations are a key driver in the progression of various cancers, notably non-small cell lung carcinoma (NSCLC). While current EGFR inhibitors show promise, resistance and side effects remain a concern. This study explores the potential of known anti-inflammat
Time & Location
24 Apr 2025, 7:00 pm – 11:00 pm
On Going Project
About the event
1. Background and Rationale:
EGFR is a receptor tyrosine kinase involved in cell proliferation, survival, and differentiation. Mutations in EGFR, such as L858R and T790M, lead to uncontrolled cell division, contributing to cancer. Although several small-molecule tyrosine kinase inhibitors (TKIs) have been developed, they face challenges like resistance development, high cost, and toxicity.
Curcumin, a bioactive compound from turmeric, exhibits anti-inflammatory, antioxidant, and anticancer properties. Structural modification of curcumin has led to derivatives with improved bioavailability and pharmacokinetics. Some of these compounds have shown activity against cancer pathways, making them promising candidates for drug repurposing.
2. Research Objectives:
To identify curcumin derivatives with high binding affinity towards common EGFR mutants.
To evaluate the stability and interaction profile of these compounds using molecular docking and molecular dynamics simulations.